Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis

被引:18
|
作者
Urshansky, Nataly
Mausner-Fainberg, Karin [2 ]
Auriel, Eitan [2 ]
Regev, Keren
Bornstein, Natan M. [2 ,3 ]
Karni, Arnon [1 ,2 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Neurol, Neuroimmunol Lab & Clin, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Dept Neurol, Stroke Unit, IL-64239 Tel Aviv, Israel
关键词
Noggin; Multiple sclerosis; T cells; Neurogenesis; OLIGODENDROCYTE PRECURSOR CELLS; REGULATORY T-CELLS; SPINAL-CORD-INJURY; DENDRITIC CELLS; NEUROTROPHIC FACTOR; STEM/PROGENITOR CELLS; FUNCTIONAL RECOVERY; GLATIRAMER ACETATE; CNS REMYELINATION; BRAIN-LESIONS;
D O I
10.1016/j.jneuroim.2010.10.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS) plaques are characterized by neurodegeneration, astrogliolis, the presence of immature oligodendrocytes and infiltrating immune cells. Recent studies revealed a putative role for noggin in both neurogenesis and oligodenrocytes development. In order to study the potential of peripheral immune cells to contribute to neurogenesis in MS, we studied the mRNA expression, protein secretion and regulation profile of noggin in peripheral blood mononuclear cells (PBMCs) of untreated patients with relapsing-remitting MS (RR-MS), interferon-beta (IFN-beta) treated RR-MS patients compared to matched healthy controls (HC). Basal levels of noggin mRNA expression, determined by quantitative real-time PCR were lower in untreated patients than in HC. No differences were found between untreated patients and IFN-beta treated patients. Similarly, the secreted levels of noggin, detected in 24 h PBMCs supernatants by ELISA, were decreased in untreated RR-MS patients than in HC. Again no significant differences were found between untreated patients and IFN-beta treated patients. Stimulation with anti-CD3/CD28 mAbs increased noggin mRNA expression in untreated patients but not in HC. However, noggin mRNA levels in untreated patients PBMCs stimulated with anti-CD3/CD28 did not reach noggin levels in unstimulated PBMCs of HC. Purification of monocytes (CD14+) and T cells (CD3+ cells) by magnet-activated cell separation has demonstrated that noggin mRNA is predominantly expressed in CD3+ cells in both HC and in RR-MS patients. This pattern also appeared in protein level of noggin, tested by Western blot. The incubation of the PBMCs with TNF-alpha increased the expression of noggin only in HC group. In conclusion, T cells possess the potential to participate in the induction of neurogeneration by the production of noggin. This potential seems to be defective in immune cells of RR-MS patients as there is reduced mRNA expression and protein secretion levels of noggin, insufficient stimulatory effect of CD3/CD28 stimulation and unresponsiveness to TNF-alpha in these patients PBMCs. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 50 条
  • [21] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [22] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [23] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [24] A retrospective analysis in patients with relapsing-remitting multiple sclerosis
    Maeurer, Mathias
    Lang, Michael
    Elias, Wolfgang
    Ries, Stefan
    Reifschneider, Stefan
    Kaefferlein, Wolfgang
    Windhagen, Susanne
    Wensdoerfer, Colin
    Niemczyk, Gabriele
    Schikhnaier, Petra
    Schwab, Stefan
    MULTIPLE SCLEROSIS, 2008, 14 : S164 - S165
  • [25] Serum neurofilament in patients with relapsing-remitting multiple sclerosis
    Brandt, A. U.
    Paul, F.
    Freing, A.
    Oberwahrenbrock, T.
    Petzold, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S269 - S270
  • [26] Vestibular rehabilitation in patients with relapsing-remitting multiple sclerosis
    Pavan, Karina
    Marangoni, Bruna E. M.
    Schmidt, Kizi B.
    Cobe, Femanda A.
    Matuti, Gabriela S.
    Nishino, Lucia K.
    Thomaz, Rodrigo B.
    Mendes, Maria Fernanda
    Lianza, Sergio
    Tilbery, Charles Peter
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2007, 65 (2A) : 332 - 335
  • [27] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [28] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [29] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [30] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):